Original title:&nbsp;Impact of Post-Procedural Aortic Regurgitation on Mortality Alter Trancatheter Aortic Valve Implantation&nbsp;Reference:&nbsp;Kentaro Hayashida, et al. J Am Coll Interv 2012;5:1247-56 Transcatheter aortic valve implantation (TAVI) sprung up as a valid strategy to treat patients with severe high risk AS (aortic stenosis). However, residual aortic regurgitation (post AR) and post-dilation remain unsolved.&nbsp; Between October 2006<a href="https://solaci.org/en/2013/01/15/aortic-insufficiency-has-a-poor-prognosis-in-tavi/" title="Read more" >...</a>

Reference:&nbsp;G&eacute;n&eacute;reux, et al, for the PARTNER Trial Investigators. JACC 2012; 60 (12):1043-62 Original title: Vascular complications after Transcatheter Aortic Valve Replacement: Insights From the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial The purpose of the study was to investigate the incidence, predictors and vascular complications impact after catheter aortic valve implantation (TAVI) in the PARTNER<a href="https://solaci.org/en/2012/10/01/vascular-complications-after-valvular-replacement-using-catheter-partner-trial-findings/" title="Read more" >...</a>

Reference: Sinning et al. AHJ Am Heart J 2012;164:102-110 Percutaneous aortic valve replacement (TAVI) is a novel technique for the treatment of severe aortic stenosis (SAS) that has been built with great enthusiasm in clinical practice, particularly in patients with excessive surgical risk. In these patients, a high obstructive peripheral vascular disease stands, a fact<a href="https://solaci.org/en/2012/10/01/tavi-more-risky-in-patients-with-peripheral-vascular-disease/" title="Read more" >...</a>